2023
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
Kummar S, Shen L, Hong D, McDermott R, Keedy V, Casanova M, Demetri G, Dowlati A, Melcón S, Lassen U, Leyvraz S, Liu T, Moreno V, Patel J, Patil T, Mallick A, Sousa N, Tahara M, Ziegler D, Norenberg R, Arvis P, Brega N, Drilon A, Tan D. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Cancer 2023, 129: 3772-3782. PMID: 37769113, PMCID: PMC11265530, DOI: 10.1002/cncr.35036.Peer-Reviewed Original ResearchConceptsTropomyosin receptor kinaseNTRK gene fusionsAdult patientsFusion sarcomaAdverse eventsData cutoffGrade 3 treatment-emergent adverse eventsTropomyosin receptor kinase fusion cancerCohort of adult patientsClinical management of adult patientsExtended survival benefitSafety of larotrectinibManagement of adult patientsGastrointestinal stromal tumorsSoft tissue sarcomasTreatment of patientsFirst-in-classGene fusionsInvestigator-assessedNTRK genesReceptor kinaseStromal tumorsSurvival benefitPediatric patientsSolid tumorsKlotho Overexpression Is Frequently Associated With Upstream Rearrangements in Fusion-Negative Phosphaturic Mesenchymal Tumors of Bone and Sinonasal Tract
Lee J, Hsieh T, Kao Y, Tsai C, Huang H, Shih C, Song H, Oda Y, Chih-Hsueh Chen P, Pan C, Sittampalam K, Petersson F, Konishi E, Chiu W, Chen C, Carpenter T, Lu T, Chang C, Huang S, Folpe A. Klotho Overexpression Is Frequently Associated With Upstream Rearrangements in Fusion-Negative Phosphaturic Mesenchymal Tumors of Bone and Sinonasal Tract. Modern Pathology 2023, 36: 100336. PMID: 37742927, DOI: 10.1016/j.modpat.2023.100336.Peer-Reviewed Original ResearchMeSH KeywordsFibroblast Growth Factor 1HumansIn Situ Hybridization, FluorescenceMesenchymomaParanasal SinusesSoft Tissue NeoplasmsTranslocation, GeneticConceptsPhosphaturic mesenchymal tumorMesenchymal tumorsSinonasal tractFibroblast growth factor 23Growth factor 23Fusion-positive casesBreak-apart fluorescenceSinonasal locationFISH-positive casesFinal cohortFactor 23Situ hybridizationUncommon neoplasmLarge cohortKlotho overexpressionFGFR1 inhibitionTumorsKL expressionCohortSoft tissueWhole genomic sequencingPromoter methylationConcordant resultsPatientsFurther investigationOutcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology
Weiss A, Chen Y, Scharschmidt T, Xue W, Gao Z, Black J, Choy E, Davis J, Fanburg-Smith J, Kao S, Kayton M, Kessel S, Lim R, Million L, Okuno S, Ostrenga A, Parisi M, Pryma D, Randall R, Rosen M, Shulkin B, Terezakis S, Venkatramani R, Zambrano E, Wang D, Hawkins D, Spunt S. Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology. Journal Of Clinical Oncology 2023, 41: 4842-4848. PMID: 37523624, PMCID: PMC10852395, DOI: 10.1200/jco.23.00045.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsChildDoxorubicinHumansIfosfamideSarcomaSoft Tissue NeoplasmsConceptsNon-rhabdomyosarcoma soft tissue sarcomasSoft tissue sarcomasRegimen BPreoperative chemoradiationRegimen ATissue sarcomasPathological responseMedian survivor follow-upComplete pathologic response ratePathological response rateEvent-free survivalPhase II studyPrimary end pointChildren's Oncology GroupIntent-to-treat analysisSurvivor follow-upNon-rhabdomyosarcomasPreoperative radiotherapyPrimary resectionOverall survivalOncology GroupII studyClinical trial updateNRG OncologyEligible patientsPhase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Signoretti S, Denize T, Cimadamore A, Wu C, Braun D, Einstein D, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal For ImmunoTherapy Of Cancer 2023, 11: e004780. PMID: 36948504, PMCID: PMC10040058, DOI: 10.1136/jitc-2022-004780.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellHumansIpilimumabNivolumabSalvage TherapySarcomaSoft Tissue NeoplasmsConceptsNivolumab/ipilimumabObjective response rateNon-clear cell renal cell carcinomaTreatment-naïve patientsCell renal cell carcinomaProgressive diseaseRenal cell carcinomaNivolumab monotherapyStable diseaseCell carcinomaAdvanced non-clear cell renal cell carcinomaMedian progression-free survivalTreatment-related adverse eventsDeath ligand 1 (PD-L1) expressionLigand 1 expressionPhase II studyProgression-free survivalWeeks of treatmentSymptomatic disease progressionEligible patientsSalvage therapyB patientsII studySalvage treatmentSarcomatoid featuresRhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
Vasquez J, Luo L, Hiniker S, Rhee D, Dasgupta R, Chen S, Weigel B, Xue W, Venkatramani R, Arndt C. Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatric Blood & Cancer 2023, 70: e30293. PMID: 36916768, PMCID: PMC10424503, DOI: 10.1002/pbc.30293.Peer-Reviewed Original ResearchMeSH KeywordsChildHumansInfantLung NeoplasmsProgression-Free SurvivalRhabdomyosarcomaRhabdomyosarcoma, EmbryonalSoft Tissue NeoplasmsConceptsEvent-free survivalMetastatic diseaseYears of ageOverall survivalOncology GroupLung metastasesExact testSoft Tissue Sarcoma CommitteeSuperior event-free survivalBetter survival outcomesKaplan-Meier methodChildren's Oncology GroupRisk stratification algorithmLog-rank testOutcome of childrenFisher's exact testN0 diseaseAggressive treatmentMetastatic rhabdomyosarcomaExtrapulmonary sitesMetastatic sitesExtremity tumorsSurvival outcomesEmbryonal histologyCOG protocolsUpdate of pediatric bone tumors—other mesenchymal tumors of bone, hematopoietic neoplasms of bone, and WHO classification of undifferentiated small round cell sarcomas of bone
Wang A, Maloney E, Al-Dasuqi K, Irshaid L, Ahmed A, Haims A, Porrino J. Update of pediatric bone tumors—other mesenchymal tumors of bone, hematopoietic neoplasms of bone, and WHO classification of undifferentiated small round cell sarcomas of bone. Skeletal Radiology 2023, 52: 1443-1463. PMID: 36656343, DOI: 10.1007/s00256-023-04286-8.Peer-Reviewed Original ResearchMeSH KeywordsBone and BonesBone NeoplasmsChildGiant Cell TumorsHematologic NeoplasmsHumansSarcomaSoft Tissue NeoplasmsWorld Health OrganizationConceptsUndifferentiated small round cell sarcomaSmall round cell sarcomasBone tumorsRound cell sarcomasPediatric populationCell sarcomaMesenchymal tumorsHematopoietic neoplasmsWorld Health Organization classificationGiant cell-rich tumorsPediatric bone tumorsOsteogenic tumorsOrganization classificationVascular tumorsNotochordal tumorsTumorsGenetic sequencing techniquesChondrogenic tumorsCertain lesionsSoft tissueBoneSarcomaNeoplasmsSeparate manuscriptDetailed update
2022
circCsnk1g3- and circAnkib1-regulated interferon responses in sarcoma promote tumorigenesis by shaping the immune microenvironment
Piras R, Ko E, Barrett C, De Simone M, Lin X, Broz M, Tessaro F, Castillo-Martin M, Cordon-Cardo C, Goodridge H, Di Vizio D, Batish M, Lawrenson K, Chen Y, Chan K, Guarnerio J. circCsnk1g3- and circAnkib1-regulated interferon responses in sarcoma promote tumorigenesis by shaping the immune microenvironment. Nature Communications 2022, 13: 7243. PMID: 36433954, PMCID: PMC9700836, DOI: 10.1038/s41467-022-34872-8.Peer-Reviewed Original ResearchMeSH KeywordsCarcinogenesisCasein Kinase IHumansInterferonsRNA, CircularSarcomaSoft Tissue NeoplasmsTumor MicroenvironmentConceptsNon-coding RNA speciesExonic circular RNAsViral RNA sensorsRNA speciesInterferon-related genesSpecific circRNAsCircular RNAsSarcoma cellsCircRNAsRNA sensorsCancer progressionFunctional contributionInterferon responseSoft tissue sarcoma cellsImmune cell recruitmentPro-tumorigenic microenvironmentCellsTumor growthSarcoma growthTumor cellsPro-inflammatory elementsCell recruitmentActivationPro-inflammatory factorsMicroenvironmentAnastomosing Hemangioma of the Ovary With Leydig Cell Hyperplasia: A Clinicopathologic Study of 12 Cases
McHenry A, Buza N. Anastomosing Hemangioma of the Ovary With Leydig Cell Hyperplasia: A Clinicopathologic Study of 12 Cases. International Journal Of Gynecological Pathology 2022, 42: 167-175. PMID: 35512214, DOI: 10.1097/pgp.0000000000000887.Peer-Reviewed Original ResearchMeSH KeywordsEndothelial CellsFemaleHemangiomaHumansHyperplasiaLeydig CellsMaleOvarian NeoplasmsOvarySoft Tissue NeoplasmsConceptsLeydig cell hyperplasiaAnastomosing hemangiomaLeydig cellsCell hyperplasiaEndothelial cellsHobnail endothelial cellsSymptomatic pelvic massSteroid cell tumorTime of resectionMultiple anatomic sitesFemale genital tractLeydig cell tumorMale genitourinary tractGlobular intracytoplasmic inclusionsHormonal manifestationsClinicopathologic studyPatient agePelvic massOvarian hilumGenitourinary tractLuteinized cellsCell tumorsVascular neoplasmVascular proliferationGenital tract
2021
Deep learning-based GTV contouring modeling inter- and intra- observer variability in sarcomas
Marin T, Zhuo Y, Lahoud R, Tian F, Ma X, Xing F, Moteabbed M, Liu X, Grogg K, Shusharina N, Woo J, Lim R, Ma C, Chen Y, El Fakhri G. Deep learning-based GTV contouring modeling inter- and intra- observer variability in sarcomas. Radiotherapy And Oncology 2021, 167: 269-276. PMID: 34808228, PMCID: PMC8934266, DOI: 10.1016/j.radonc.2021.09.034.Peer-Reviewed Original ResearchMeSH KeywordsDeep LearningHumansObserver VariationRadiotherapy Planning, Computer-AssistedReproducibility of ResultsSarcomaSoft Tissue NeoplasmsConceptsGross tumor volumeRadiation therapy treatment planningGross tumor volume contoursGross tumor volume delineationTherapy treatment planningIntra-observer variabilityConsensus contoursGTV contoursPre-operative CT imagesSoft tissue sarcomasRadiation oncologistsTumor volumeBone sarcomasTreatment planningAccurate contoursCT imagesDelineation procedureSarcomaSoft tissueConfidence levelRadiationPatientsHausdorff distanceMultiple contoursX-ray
2020
Synovial Myxoma: Found in Canines, Rabbits, and Now Humans Too?: A Case Report.
Munger AM, Ibe IK, Rottmann D, Conway D, Costa J, Lindskog DM. Synovial Myxoma: Found in Canines, Rabbits, and Now Humans Too?: A Case Report. JBJS Case Connector 2020, 10: e0490. PMID: 32224675, DOI: 10.2106/jbjs.cc.19.00490.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAnimalsFemaleHumansKnee JointMiddle AgedMyxomaSoft Tissue NeoplasmsSynovectomySynovial MembraneConceptsSynovial myxomaCase reportRight knee painYear old womanCluster of differentiationLow proliferative activityAggressive massKnee painPathologic reviewIntralesional resectionArthroscopic synovectomyKnee aspirationSynovial cellsInfiltrative tumorsMyxoid stromaProliferative activityPainSynovectomyMyxomaSlow growingReportResectionPatientsEffusionHumans
2019
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Jañez N, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, Carrasco E, Dickler MN, Group G, GBG, Oncology A. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. European Journal Of Cancer 2019, 117: 91-98. PMID: 31276981, PMCID: PMC6718694, DOI: 10.1016/j.ejca.2019.06.002.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBone NeoplasmsBreast NeoplasmsEvaluation Studies as TopicFemaleFollow-Up StudiesFulvestrantHumansLetrozoleMiddle AgedNeoplasm Recurrence, LocalPrognosisReceptors, EstrogenReceptors, ProgesteroneSoft Tissue NeoplasmsSurvival RateTamoxifenConceptsProgression-free survivalClinical benefit rateObjective response rateEndocrine therapyMetastatic breast cancerOverall survivalGrade IIIBreast cancerHormone receptor-positive metastatic breast cancerMedian progression-free survivalAddition of BevSignificant additional toxicityStandard endocrine therapyDe novo diseaseAddition of bevacizumabFirst-line treatmentPredictors of efficacyNovo diseaseRecurrent diseaseLiver eventsEndocrine sensitivityBenefit rateAdditional toxicityPatientsResponse rate
2018
Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma
Zhu G, Benayed R, Ho C, Mullaney K, Sukhadia P, Rios K, Berry R, Rubin B, Nafa K, Wang L, Klimstra D, Ladanyi M, Hameed M. Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Modern Pathology 2018, 32: 609-620. PMID: 30459475, PMCID: PMC6486453, DOI: 10.1038/s41379-018-0175-7.Peer-Reviewed Original ResearchConceptsRNA sequencing assayFusion partnerClinical molecular diagnostic assaySequencing assayIn-frame fusion transcriptsFusion transcriptsDetection of gene fusionsSoft tissue tumorsOncogenic fusion transcriptsAnchored multiplex PCRMolecular diagnostic assaysPseudomyogenic hemangioendotheliomaSolid tumorsTissue tumorsTumor typesClinical management of sarcomasMultiplex PCRRNA sequencingGene fusionsTRPS1-PLAG1Molecular methodsCase of pseudomyogenic hemangioendotheliomaClinical specimensRNASequencing stepAssociation of Facility and System Factors With Survival Among Pediatric Patients With Surgically Treated Head and Neck Sarcomas
Cheraghlou S, Li H, Judson BL. Association of Facility and System Factors With Survival Among Pediatric Patients With Surgically Treated Head and Neck Sarcomas. JAMA Otolaryngology - Head & Neck Surgery 2018, 144: 455-456. PMID: 29800240, PMCID: PMC6136052, DOI: 10.1001/jamaoto.2018.0183.Peer-Reviewed Original Research
2016
Characterization of FN1–FGFR1 and novel FN1–FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors
Lee JC, Su SY, Changou CA, Yang RS, Tsai KS, Collins MT, Orwoll ES, Lin CY, Chen SH, Shih SR, Lee CH, Oda Y, Billings SD, Li CF, Nielsen GP, Konishi E, Petersson F, Carpenter TO, Sittampalam K, Huang HY, Folpe AL. Characterization of FN1–FGFR1 and novel FN1–FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Modern Pathology 2016, 29: 1335-1346. PMID: 27443518, DOI: 10.1038/modpathol.2016.137.Peer-Reviewed Original ResearchConceptsPhosphaturic mesenchymal tumorFN1-FGFR1 fusionMesenchymal tumorsGiant cell tumorFusion geneSolitary fibrous tumorPotential morphologic mimicsFN1-FGFR1Cell tumorsOverall prevalenceFGF23 secretionFibrous tumorFusion statusMorphologic mimicsLarge seriesAutocrine loopAdditional casesTumorsWestern blotPrior studiesFurther studiesSitu hybridization analysisDirect sequencingFusion typeImmunohistochemistry
2015
Survival Following Lung Metastasectomy in Soft Tissue Sarcomas
Giuliano K, Sachs T, Montgomery E, Guzzetta A, Brock M, Pawlik TM, Yang SC, Ahuja N. Survival Following Lung Metastasectomy in Soft Tissue Sarcomas. The Thoracic And Cardiovascular Surgeon 2015, 64: 150-158. PMID: 26339728, DOI: 10.1055/s-0035-1563538.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantKaplan-Meier EstimateLung NeoplasmsMaleMetastasectomyMiddle AgedNeoplasm GradingPneumonectomyRetrospective StudiesRisk FactorsSarcomaSoft Tissue NeoplasmsThoracoscopyTime FactorsTreatment OutcomeYoung AdultConceptsDisease-free intervalSoft tissue sarcomasLung metastasectomyTissue sarcomasLonger disease-free intervalLower pathologic gradeMedian overall survivalKaplan-Meier estimatesLog-rank testLow-grade tumorsGreatest survival advantageOverall survivalPostoperative factorsImproved survivalPatient selectionTumor characteristicsPathologic gradeMetastasis diagnosisCommon siteSurvival advantageSurvival analysisYounger ageMetastasectomyPatientsSurvivalBiologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines
Goldberg J, Fisher D, Demetri G, Neuberg D, Allsop S, Fonseca C, Nakazaki Y, Nemer D, Raut C, George S, Morgan J, Wagner A, Freeman G, Ritz J, Lezcano C, Mihm M, Canning C, Hodi F, Dranoff G. Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clinical Cancer Research 2015, 21: 3178-3186. PMID: 25805798, PMCID: PMC4506240, DOI: 10.1158/1078-0432.ccr-14-2932.Peer-Reviewed Original ResearchConceptsAlveolar soft part sarcomaClear cell sarcomaGranulocyte-macrophage colony-stimulating factorColony-stimulating factorSoft part sarcomaTissue-type plasminogen activatorMicrophthalmia transcription factorGM-CSFReplication-defective adenoviral vector encoding GM-CSFSecrete granulocyte-macrophage colony-stimulating factorCCS patientsImmune-mediated tumor destructionT-cell-mediated delayed-type hypersensitivity reactionCD8(+) T cellsAdenoviral-mediated gene transferPhase I clinical trialDelayed-type hypersensitivity reactionAutologous tumor cellsPD-ligand 1Sarcoma cellsNo tumor regressionRare mesenchymal malignancySingle-cell suspensionsTumor regressionMetastatic tumors
2014
Neuroblastoma Presenting as Facial Nerve Palsy and Bulging Tympanic Membrane
Bernson-Leung M, Ananth P, Shusterman S. Neuroblastoma Presenting as Facial Nerve Palsy and Bulging Tympanic Membrane. Clinical Pediatrics 2014, 54: 183-185. PMID: 24817076, DOI: 10.1177/0009922814534314.Peer-Reviewed Original ResearchLipoblastoma of the Hand and Cleft Palate
Alperovich M, Ayo D, Staffenberg DA, Sharma S. Lipoblastoma of the Hand and Cleft Palate. Journal Of Craniofacial Surgery 2014, 25: e189-e191. PMID: 24621768, DOI: 10.1097/scs.0000000000000628.Peer-Reviewed Original ResearchMeSH KeywordsChromosome AberrationsChromosomes, Human, Pair 8Cleft PalateFemaleGenetic Association StudiesHandHumansInfantLipoblastomaSoft Tissue NeoplasmsConceptsCleft palateImportant genetic risk factorCleft palate developmentRare benign neoplasmGenetic risk factorsCase of lipoblastomaFemale patientsRare tumorRisk factorsClonal chromosomal rearrangementsBenign neoplasmsPotential genetic associationsAdipose tissueCytogenetic testingPalateLipoblastomaPatientsGenetic associationPalate development
2013
Extrathoracic Location and “Borderline” Histology are Associated with Recurrence of Solitary Fibrous Tumors After Surgical Resection
Wilky BA, Montgomery EA, Guzzetta AA, Ahuja N, Meyer CF. Extrathoracic Location and “Borderline” Histology are Associated with Recurrence of Solitary Fibrous Tumors After Surgical Resection. Annals Of Surgical Oncology 2013, 20: 4080-4089. PMID: 24046107, PMCID: PMC4124630, DOI: 10.1245/s10434-013-3241-x.Peer-Reviewed Original ResearchConceptsExtrathoracic solitary fibrous tumorsBenign solitary fibrous tumorSolitary fibrous tumorMalignant histologyExtrathoracic locationPathologic criteriaFibrous tumorMetastatic solitary fibrous tumorPatient pathology reportsKaplan-Meier methodPredictors of recurrencePrimary care physiciansHead/neckSurgical pathology databaseMethodsWith IRB approvalSFTS patientsSurgical resectionComplete resectionCare physiciansWorse prognosisIntraabdominal sitesPathology databaseMedical recordsPathology reportsPatient historySingle-institution Outcome Experience Using AlloDerm® as Temporary Coverage or Definitive Reconstruction for Cutaneous and Soft Tissue Malignancy Defects
Deneve J, Turaga K, Marzban S, Puleo C, Sarnaik A, Gonzalez R, Sondak V, Zager J. Single-institution Outcome Experience Using AlloDerm® as Temporary Coverage or Definitive Reconstruction for Cutaneous and Soft Tissue Malignancy Defects. The American Surgeon 2013, 79: 476-482. PMID: 23635582, PMCID: PMC4505800, DOI: 10.1177/000313481307900522.Peer-Reviewed Original ResearchMeSH KeywordsAcellular DermisAdultAgedAged, 80 and overCarcinomaCellulitisCollagenDermatofibrosarcomaFemaleHumansMaleMelanomaMiddle AgedPlastic Surgery ProceduresPostoperative ComplicationsRetrospective StudiesSkin NeoplasmsSkin TransplantationSoft Tissue NeoplasmsSurgical FlapsTreatment OutcomeWound HealingConceptsAlloDerm reconstructionInstitutional review board-approved review of patientsDefinitive reconstructionInstitutional review board-approved reviewReview of patientsHead and neckSoft tissue malignancyMedian defect sizeSoft tissue resectionSplit-thickness skin graftEarly postoperative findingsComplex surgical defectsSoft tissue defectsAdjuvant radiationPositive marginsOral antibioticsSingle-institutionClinicopathological variablesCosmetic outcomePostoperative examinationFrequent complicationPostoperative findingsMalignant defectsSurgical defectsTissue malignancy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply